Visit us at our booth to speak with our technical experts. Stop by and learn how our solutions and other innovations can help you succeed in a competitive hAPI market.

March 18-20, 2019

Big Sight Exhibition Center - East Hall 1, 2 and 3
Tokyo, Japan

Booth H-20

Use exceptional networking opportunities and discover Heraeus` products and solutions by talking to our experts directly! Our technical and commercial specialists for pharmaceutical ingredients provide professional consulting and are looking forward to discussing your current projects, processes and challenges.

The highest purity of our active pharmaceutical ingredients guarantees you effective processes and consistent high quality of your products.

Heraeus supports you from the research stage to registration to market launch of anti-cancer hAPIs as well as in the exclusive synthesis of cytotoxic compounds.

Our Generic Products:

• Cisplatin
• Carboplatin
• Oxaliplatin
• Dacarbazine
• Thiotepa
• Bendamustine hydrochloride monohydrate

Read more here.

Sato-san, what does your job at Heraeus entail?

I am a General Manager for Sales in Japan for Heraeus K. K. and support our partners in Japan for our hAPI businesses. In addition, my role is to find CDMO (Contract Development and Manufacturing Organization) opportunities with Japanese customers using business networks established by Heraeus K.K. I also collect API-related information which are solely published in Japanese, and are obtained informally.

What are Heraeus’ main strengths in the Japanese hAPI market?

The reliability of our product supply for the long term as well as R&D, QC, and administrative job capability are what set us apart. In addition, our customer-oriented mindset and behavior are also key strengths. Since Germany has a well-developed infrastructure and is politically stable, our production site in Hanau has an advantage for Japanese customers who are concerned about natural disasters such as earthquakes and volcanic eruptions – concerns expressed by the BCP in Japan.

What are your expectations for your visit to the CPhI in Tokyo?

Like in all previous years, we expect a number of individual meetings with existing customers and partners. This is always a top priority. We also hope to attract new visitors to our booth with the goal of creating new business opportunities. And last but not least, we expect to learn about the latest trends, activities, and our competitors in the API industry.

Make your appointment to meet Akira Sato here.

Dr. Hannakam, how long has Heraeus been producing platinum-based ingredients for cancer treatment?

Heraeus has been manufacturing active pharmaceutical ingredients for over 30 years. It all started with the synthesis of Cisplatin in 1980: It was produced as a catalytic compound at that time and had proven itself as effective in combatting cancer cells. Since then, Heraeus has become the market leader for the platinum-based ingredients Cisplatin, Oxaliplatin, and Carboplatin.

For you, what is the most important in sales?

The excellent long-term relationship with our customers is always in focus. It is very important for our customers to rely on us as partner and on the top quality of our products. This results in a lower failure rate in their own production processes while also ensuring the quality of their own products. Additionally, our products always include a “full service package”, which includes our support for approvals and documentation for the authorities.

What are your expectations for the CPhI in Tokyo?

Heraeus attended the CPhl for many years, and never were we disappointed. The entire industry gathers there, and we see many of our existing customers at the trade show. Our management team is involved, and our calendars are well booked with appointments. At the same time, I’m especially excited about new visitors to our booth, which has been designed to be much more personal this year. You may be surprised!